

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 OR 15(D) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): October 31, 2003

Celsion Corporation

(Exact Name of Registrant as Specified in Charter)

Delaware

000-14242

52-1256615

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

10220-L Old Columbia Road, Columbia, Maryland

21046-1705

(Address of principal executive office)

(Zip Code)

Registrant's telephone number, including area code: (410) 290-5390

(Former Name or Former Address, if Changed Since Last Report)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CELSION CORPORATION

Date: December 3, 2003

By: /s/ Anthony P. Deasey

Executive Vice President—Finance and
Administration and Chief Financial Officer

EXHIBIT INDEX

Exhibit	Description
99.1	Registrant's Press Release dated December 3, 2003

For Further Information Contact:

Tony Deasey
Celsion Corporation
410.290.5390
tony@celsion.com

Steve Chizzik/Ira Weingarten
Equity Communications
973.912.0980
equity@silcom.com

Richard Cooper/Jennifer Zimmons
StrategicGrowth International, Inc.
212.838.1444
info@sgi-ir.com

CELSION CHANGES FISCAL YEAR END

Columbia, MD –December 03, 2003: CELSION CORPORATION (AMEX: CLN) today announced that, effective December 31, 2003, it is changing its fiscal year end from September 30 to December 31.

Anthony P. Deasey, Celsion's Chief Financial Officer, commented, "In January of this year, we formed a strategic relationship with Boston Scientific Corporation through which we have agreed to distribute our BPH 800 Microwave Urethroplasty™ product at such time as it is approved by the FDA. This change to a calendar year end will bring our financial year into conformity with that of Boston Scientific Corporation."

About Celsion: Celsion Corporation, based in Columbia, Maryland, is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused-heat energy delivered by patented microwave technology.

In January 2003, Celsion entered into a strategic alliance with Boston Scientific Corporation (NYSE:BSX) in which Boston Scientific will initially distribute Celsion's BPH product worldwide. Boston Scientific currently owns approximately 7% of Celsion's outstanding stock.

Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

###